Skip to main content
. 2021 Nov 20;111(4):939–949. doi: 10.1002/cpt.2485

Figure 4.

Figure 4

Correlations between platelet count and sTXB2 at the end of the randomized phase of the ARES trial according to cytoreduction. The plots depict the correlations between platelet count and sTXB2 at visit 3 (i.e., at the end of each randomized treatment; i.e., aspirin once‐ n = 73, twice‐daily n = 71, or three times‐daily n = 74). The sTXB2 levels are expressed as ng/mL of serum (panel a) or as ng/105 platelets (panel b).